CL2017003000A1 - Conjugados fluorescentes - Google Patents

Conjugados fluorescentes

Info

Publication number
CL2017003000A1
CL2017003000A1 CL2017003000A CL2017003000A CL2017003000A1 CL 2017003000 A1 CL2017003000 A1 CL 2017003000A1 CL 2017003000 A CL2017003000 A CL 2017003000A CL 2017003000 A CL2017003000 A CL 2017003000A CL 2017003000 A1 CL2017003000 A1 CL 2017003000A1
Authority
CL
Chile
Prior art keywords
fraction
conjugate
fluorescent conjugates
objective
antibody
Prior art date
Application number
CL2017003000A
Other languages
English (en)
Inventor
Francoise Cailler
Bérénice Framery
Original Assignee
Surgimab S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surgimab S A S filed Critical Surgimab S A S
Publication of CL2017003000A1 publication Critical patent/CL2017003000A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

<p>LA INVENCIÓN PROPORCIONA UN CONJUGADO CON UNA FRACCIÓN DE FLUOROCROMO F ACOPLADA A UNA FRACCIÓN OBJETIVO T. LA FRACCIÓN F SE DESCRIBE MEDIANTE LA FÓRMULA (1), Y LA FRACCIÓN OBJETIVO T SE CARACTERIZA POR TENER AFINIDAD CON UN MARCADOR TUMORAL, TAL COMO UN ANTICUERPO O FRAGMENTO DE ANTICUERPO. EL CONJUGADO PUEDE UTILIZARSE PARA DIAGNÓSTICO DE TUMORES, INCLUYENDO LA FOTODETECCIÓN DE NÓDULOS TUMORALES DURANTE LA CIRUGÍA DE RESECCIÓN.</p>
CL2017003000A 2015-06-03 2017-11-27 Conjugados fluorescentes CL2017003000A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15170617 2015-06-03

Publications (1)

Publication Number Publication Date
CL2017003000A1 true CL2017003000A1 (es) 2018-05-18

Family

ID=53365860

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003000A CL2017003000A1 (es) 2015-06-03 2017-11-27 Conjugados fluorescentes

Country Status (23)

Country Link
US (2) US9821079B2 (es)
EP (1) EP3166606B1 (es)
JP (1) JP6912389B2 (es)
KR (1) KR20180014027A (es)
CN (1) CN107949385B (es)
AR (1) AR104895A1 (es)
AU (1) AU2016271853B2 (es)
CA (1) CA2986078C (es)
CL (1) CL2017003000A1 (es)
DK (1) DK3166606T3 (es)
ES (1) ES2683554T3 (es)
HR (1) HRP20181164T1 (es)
HU (1) HUE038696T2 (es)
IL (1) IL255633B (es)
MX (1) MX2017015036A (es)
NZ (1) NZ737353A (es)
PL (1) PL3166606T3 (es)
PT (1) PT3166606T (es)
RU (1) RU2720976C2 (es)
TR (1) TR201810532T4 (es)
TW (1) TWI702259B (es)
WO (1) WO2016193396A1 (es)
ZA (1) ZA201707817B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038696T2 (hu) * 2015-06-03 2018-11-28 Surgimab S A S Fluoreszcens konjugátumok
ES2911273T3 (es) * 2019-03-19 2022-05-18 Miltenyi Biotec Bv & Co Kg Método para proporcionar células personalizadas con receptores de antígeno quimérico (CAR)
CN112851809A (zh) * 2021-01-20 2021-05-28 上海交通大学 一种抗终末糖基化蛋白受体的抗体及其应用
WO2023114248A1 (en) * 2021-12-16 2023-06-22 Curadel Surgical Innovations, Inc. Near-infrared fluorescent contrast bioimaging agents for imaging of sentinel lymph nodes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095758A (ja) * 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
AU2097500A (en) * 1999-12-15 2001-06-25 Fuji Photo Film Co., Ltd. Near infrared fluorescent contrast agent and fluorescence imaging
WO2006036071A2 (en) * 2004-09-29 2006-04-06 Ge Healthcare As Urokinase plasminogen activator receptor targeted contrast agent
FR2889700B1 (fr) * 2005-08-11 2012-11-23 Synthinnove Lab Marqueurs, leur procede de fabrication et leurs applications
WO2009107139A1 (en) * 2008-02-27 2009-09-03 Yeda Research And Development Co. Ltd Rgd-(bacterio)chlorophyll conjugates for photodynamic therapy and imaging of necrotic tumors
US8906612B2 (en) * 2010-08-25 2014-12-09 Pacific Biosciences Of California, Inc. Scaffold-based polymerase enzyme substrates
WO2012054749A1 (en) * 2010-10-20 2012-04-26 Li-Cor, Inc. Cyanine dyes and their conjugates
US9751868B2 (en) * 2012-02-28 2017-09-05 Pierce Biotechnology, Inc. Benzocyanine compounds
HUE038696T2 (hu) * 2015-06-03 2018-11-28 Surgimab S A S Fluoreszcens konjugátumok

Also Published As

Publication number Publication date
JP6912389B2 (ja) 2021-08-04
TW201708407A (zh) 2017-03-01
US10159757B2 (en) 2018-12-25
EP3166606B1 (en) 2018-05-09
AR104895A1 (es) 2017-08-23
BR112017025935A2 (pt) 2018-08-14
AU2016271853A1 (en) 2017-12-07
HUE038696T2 (hu) 2018-11-28
TR201810532T4 (tr) 2018-08-27
IL255633B (en) 2020-09-30
RU2017141422A (ru) 2019-07-09
DK3166606T3 (en) 2018-08-13
WO2016193396A1 (en) 2016-12-08
PL3166606T3 (pl) 2018-10-31
CA2986078A1 (en) 2016-12-08
RU2017141422A3 (es) 2019-10-28
ES2683554T3 (es) 2018-09-26
AU2016271853B2 (en) 2020-10-22
CN107949385B (zh) 2021-04-09
TWI702259B (zh) 2020-08-21
CN107949385A (zh) 2018-04-20
US9821079B2 (en) 2017-11-21
ZA201707817B (en) 2019-11-27
US20170035915A1 (en) 2017-02-09
RU2720976C2 (ru) 2020-05-15
IL255633A (en) 2018-01-31
KR20180014027A (ko) 2018-02-07
MX2017015036A (es) 2018-06-07
EP3166606A1 (en) 2017-05-17
NZ737353A (en) 2023-12-22
CA2986078C (en) 2023-09-12
HRP20181164T1 (hr) 2018-09-21
JP2018525329A (ja) 2018-09-06
US20180126009A1 (en) 2018-05-10
PT3166606T (pt) 2018-10-01

Similar Documents

Publication Publication Date Title
CL2017003000A1 (es) Conjugados fluorescentes
EA201990615A1 (ru) Пирролобензодиазепиновые конъюгаты
CY1124402T1 (el) Προϊοντα συζευξης πυρρολοβενζοδιαζεπινης-αντισωματος
EA201590424A1 (ru) Пирролбензодиазепины и их конъюгаты
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
UY32730A (es) Inhibidores de cyp17
CO6420350A2 (es) Proteinas de union especificas y sus usos
GT201200339A (es) Compuestos, composiciones de tioacetato y mètodos de uso
CY1120123T1 (el) Μονοκλωνικα αντισωματα κατα της gt468 για τη θεραπεια του καρκινου
ECSP11011420A (es) Procedimientos para mejorar la farmacocinética
EA201591665A1 (ru) Оральные составы деферазирокса
RU2012148909A (ru) Новый синтез соединений тиазолидиндиона
CO6650346A2 (es) Composiciones de tetraciclina
EA201890221A1 (ru) Hbed-бисфосфонаты, их конъюгаты с радиометаллом и их применение в качестве лечебно-диагностических агентов
GT201000080A (es) Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida
RU2011127771A (ru) 2,6-диизоборнилфенолы
DOP2011000296A (es) Compuesto de pirazol
RU2011132708A (ru) Ароматические блок-сополиэфирсульфоны
RU2010143923A (ru) Ненасыщенные блок-сополиэфирсульфоны
RU2010130104A (ru) 2-(1&#39;-гидрокси-4&#39;-изопропилен-1&#39;-метилциклогексил-2&#39;-тио)-метилэтаноат, обладающий фунгицидным и противовоспалительным действием
RU2013142537A (ru) Ароматические полиэфиры
RU2013130187A (ru) Ароматические блок-сополиэфиры
RU2012126276A (ru) Огнестойкие блок-сополиэфирсульфоны
RU2013142538A (ru) Ароматические полиэфирсульфонкетоны
DOP2017000016A (es) Nueva sal de disoproxilo de tenofovir